Blood disorders in children are complex and vary in frequency. Investigators are working to understand how hematologic disorders develop and are working to improve the recognition of biomarkers of thromboembolic disease in order to advance diagnosis and treatment. Studies also aim to identify which hematology patients may truly benefit from treatment strategies that have become standard of care in adults.
Length of Stay and Treatment-Related Complications are Similar in Pediatric and Adolescent and Young Adult Patients with Bone Sarcoma
Adolescent and young adult (AYA) cancer patients have been shown to have unique clinical characteristics and inferior outcomes compared to younger patients. This study found that in US children's hospitals, adult and young adult patients with sarcomas do not have prolonged length of stay or an increased risk of the most common treatment-related complications as compared to younger patients.
Access an abstract of this study: Length of stay and treatment-related complications are similar in pediatric and AYA patients with bone sarcoma in United States children's hospitals. Pediatr Blood Cancer. 2012 Jun 15. doi: 10.1002/pbc.24231. [Epub ahead of print]
Current and Future Management of Pediatric Venous Thromboembolism
The purpose of this review is to summarize the epidemiology, current and emerging pharmacotherapeutic options, and management of venous thromboembolism in children.
Access an abstract of this study: Current and future management of pediatric venous thromboembolism. Am J Hematol. 2012 Jan 25. doi: 10.1002/ajh.23131. [Epub ahead of print]
Levetiracetam May Lead to Better Dose Assurance of Busulfan During Hematopoietic Stem Cell Transplantation
Anti-seizure prophylaxis is routinely utilized during busulfan administration for hematopoietic stem cell transplantation. We evaluated the feasibility and efficacy of levetiracetam in children undergoing hematopoietic stem cell transplantation.
Access an abstract of this study: Levetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation. Pediatr Blood Cancer. 2012 Feb 29. doi: 10.1002/pbc.24126. [Epub ahead of print]
Burkitt's Leukemia with an Atypical Immunophenotype: A Case Report
Burkitt's leukemia (BL) constitutes a small but important fraction of acute leukemias in children. This paper describes an atypical case in a 12-year-old girl and emphasizes that correct classification and treatment starts with proper morphologic/immunophenotypic correlation, and the awareness of the overlapping features in some cases.
Access an abstract of this study: Burkitt's Leukemia with an Atypical Immunophenotype: Report of a Case and Review of Literature. Lab Hematol. 2011 Dec 1;17(4):27-31.
TACL T2009-012 A Phase I Dose Finding Study of Drug in Children with Refractory Hematologic Malignancies, Children's Hospital of Los Angeles (Laura Martin)
A Phase III Open Trial to Demonstrate Safety and Efficacy of Prophylaxis and On-Demand Therapy in Children with Severe Hemophilia A Treated with Study Drug, Anonymous (Bryce Kerlin)
Tranexamic Acid in Adolescents with Cyclic Heavy Menstrual Bleeding, Anonymous (Sarah O’Brien)
Retreatment with Study Drug in Patients with CD30-Positive Hematologic Malignancies, Anonymous (Randal Olshefski)
Patient and Family Support Group for Hemophilia Clinic, Cascade (Bryce A. Kerlin, MD)
Dr. O’Brien Chosen as Hematology Webinar Presenter
Sarah O’Brien, MD, MSc, member of the Division of Hematology, Oncology & BMT, was chosen as one of three physicians nationally to present to more than 200 international hematologists through an American Socieity of Hematology webinar. The webinar focused on the basic science, laboratory diagnosis and use of the clinical history to guide diagnosis of non-hemophilia bleeding conditions.